Calcium antagonists: their role in neuroprotection.
Hunter
A J
AJ
SmithKline Beecham Pharmaceuticals, New Frontiers Science Park, Harlow, Essex, UK.
D000818:Animals; D002545:Brain Ischemia / Q000150:complications / Q000503:physiopathology*; D002121:Calcium Channel Blockers / Q000009:adverse effects / Q000494:pharmacology*; D015220:Calcium Channels / Q000145:classification / Q000187:drug effects*; D002561:Cerebrovascular Disorders / Q000209:etiology / Q000503:physiopathology*; D004095:Dihydropyridines / Q000494:pharmacology; D005444:Flunarizine / Q000494:pharmacology; D006801:Humans; D018696:Neuroprotective Agents / Q000009:adverse effects / Q000494:pharmacology*; D014700:Verapamil / Q000031:analogs & derivatives / Q000494:pharmacology
D002121:Calcium Channel Blockers; D015220:Calcium Channels; D004095:Dihydropyridines; D018696:Neuroprotective Agents; D014700:Verapamil; C052752:emopamil; D005444:Flunarizine